BRAF and non-small cell lung carcinoma: Peripheral edema is a common adverse event and has been reported to occur in 28%–36% of cases of BRAF V600E‐mutant NSCLC,3, 21 but most patients experienced mild (grade 1 or 2) peripheral edema.